Lantern Pharma Inc.
Lantern Pharma (Nasdaq: LTRN) is an oncology-focused biotechnology company that uses artificial intelligence, machine learning and genomic data to discover and develop cancer therapies. Its RADR® platform analyzes oncology data to identify drug candidates, biomarkers and patient groups that may respond to treatment,… From the company’s description.
In fiscal 2025, Lantern Pharma Inc. reported a net loss of $17.12M. Operations used $15.68M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Lantern Pharma Inc. does
In the company’s own words
Lantern Pharma (Nasdaq: LTRN) is an oncology-focused biotechnology company that uses artificial intelligence, machine learning and genomic data to discover and develop cancer therapies. Its RADR® platform analyzes oncology data to identify drug candidates, biomarkers and patient groups that may respond to treatment, supporting both the development of new compounds and the repurposing of previously tested candidates. Lantern’s pipeline includes three clinical-stage small-molecule candidates: LP-300, LP-184 and LP-284, targeting solid tumors and blood cancers, as well as a preclinical antibody-drug conjugate program. Through wholly owned subsidiary Starlight Therapeutics, it develops LP-184 for central nervous system and brain cancers, where the compound is also called STAR-001. Lantern also offers AI research tools, including PredictBBB, which predicts blood-brain barrier permeability, and withZeta, a generative AI platform for rare cancer research. RADR® incorporates more than 200 billion oncology-focused data points and over 200 machine-learning algorithms. The company plans to offer AI platforms and related research services to biopharma companies, researchers and drug developers.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DALLAS, TX
- Fiscal year end
- December
- CIK
- 1763950
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Lantern Pharma Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Lantern Pharma Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Lantern Pharma Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Lantern Pharma Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Lantern Pharma Inc.'s last four quarterly filings that the numbers alone won't show?”